Diosynvax
Diosynvax is a startup headquartered in Hertford, United Kingdom, founded in 2017. It has won about £2.09m in competitive Innovate UK grants since 2023, according to UK Research and Innovation.
Part of the 311 Institute Global Startups Directory. Last updated .
Innovation grants
Diosynvax has won about £2.09m in competitive Innovate UK grants since 2023.
- A Broadly Protective, Thermostable and Rapidly Deployable Pre-Pandemic pan-H5Nx Influenza Vaccine with mucosal delivery potential (£312k, 2025)
- Clinical development of DIOS-HFVac3: A pre-clinically effective multivalent vaccine for Lassa fever virus, Marburg virus, and Sudan ebolavirus (£1.78m, 2023)
R&D ecosystem
Diosynvax sits inside the London and the Golden Triangle R&D ecosystem in the Global R&D Labs Directory.
Related
Questions and answers
What does Diosynvax do?
Diosynvax works in biotechnology. Its Innovate UK projects include: A Broadly Protective, Thermostable and Rapidly Deployable Pre-Pandemic pan-H5Nx Influenza Vaccine with mucosal delivery potential.
Where is Diosynvax based?
Diosynvax is headquartered in Hertford, United Kingdom.
When was Diosynvax founded?
Diosynvax was founded in 2017.
Source records: Companies House and UK Research and Innovation.
© 311 Institute 2026. Facts from the official sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.